Abstract
Respiratory RNA viruses are constantly evolving, thus requiring development of additional prophylactic and therapeutic strategies. Harnessing the innate immune system to non-specifically respond to viral infection has the advantage of being able to circumvent viral mutations that render the virus resistant to a particular therapeutic agent. Viruses are recognized by various cellular receptors, including Toll-like receptor (TLR) 3 which recognizes doublestranded (ds)RNA produced during the viral replication cycle. TLR3 agonists include synthetic dsRNA such as poly (IC), poly (ICLC) and poly (AU). These agents have been evaluated and found to be effective against a number of viral agents. One major limitation has been the toxicity associated with administration of these drugs. Significant time and effort have been spent to develop alternatives/modifications that will minimize these adverse effects. This review will focus on the TLR3 agonist, poly (IC)/(ICLC) with respect to its use in treatment/prevention of respiratory viral infections.
Keywords: Coronavirus, influenza, innate immune system, respiratory syncytial virus, rhinovirus, poly (ICLC), Toll-like receptor 3
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Volume: 10 Issue: 5
Author(s): M. E. Christopher and J. P. Wong
Affiliation:
Keywords: Coronavirus, influenza, innate immune system, respiratory syncytial virus, rhinovirus, poly (ICLC), Toll-like receptor 3
Abstract: Respiratory RNA viruses are constantly evolving, thus requiring development of additional prophylactic and therapeutic strategies. Harnessing the innate immune system to non-specifically respond to viral infection has the advantage of being able to circumvent viral mutations that render the virus resistant to a particular therapeutic agent. Viruses are recognized by various cellular receptors, including Toll-like receptor (TLR) 3 which recognizes doublestranded (ds)RNA produced during the viral replication cycle. TLR3 agonists include synthetic dsRNA such as poly (IC), poly (ICLC) and poly (AU). These agents have been evaluated and found to be effective against a number of viral agents. One major limitation has been the toxicity associated with administration of these drugs. Significant time and effort have been spent to develop alternatives/modifications that will minimize these adverse effects. This review will focus on the TLR3 agonist, poly (IC)/(ICLC) with respect to its use in treatment/prevention of respiratory viral infections.
Export Options
About this article
Cite this article as:
E. Christopher M. and P. Wong J., Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050327
DOI https://dx.doi.org/10.2174/1871523011109050327 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diquaternized Curarelike Myorelaxants: Structure and Biological Activity
Mini-Reviews in Medicinal Chemistry Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Potential Novel Anxiolytic Drugs
Current Pharmaceutical Design Impact of Clozapine, N-Desmethylclozapine and Chlorpromazine on Thromboxane Production in Vitro
Medicinal Chemistry Hairy Roots, their Multiple Applications and Recent Patents
Recent Patents on Biotechnology The Oxygen Therapy
Current Medicinal Chemistry Inhalational Anesthetics in Acute Severe Asthma
Current Drug Targets Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Ethanol Withdrawal and Hyperalgesia
Current Drug Abuse Reviews Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life
Current Diabetes Reviews Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Cognitive Decline as a Consequence of Essential Hypertension
Current Pharmaceutical Design Renal Microcirculation and Calcium Channel Subtypes
Current Hypertension Reviews